Inhibikase Therapeutics Inc (IKT) — Cash Flow Reinvestment Rate
Latest as of September 2020:
0.00x
Inhibikase Therapeutics Inc (IKT) has a Cash Flow Reinvestment Rate of 0.00x as of September 2020, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $75.52K. See IKT equity to assets ratio to measure how much of total assets are equity-financed.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
$0.00
Capex + Investments
Operating Cash Flow
$75.52K
USD
Capital Expenditures
$0.00
USD
Inhibikase Therapeutics Inc Cash Flow Reinvestment Rate (2018–2018)
Historical reinvestment intensity for Inhibikase Therapeutics Inc across 1 annual periods. Also explore IKT total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Inhibikase Therapeutics Inc (2018–2018)
Year-by-year capital reinvestment analysis for Inhibikase Therapeutics Inc. For live market cap and broader valuation context, see market value of Inhibikase Therapeutics Inc.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 0.12x | $87.10K | $714.99K | $0.00 | — |
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow